arrow
J

Jacqueline Cloos

vrije universiteit amsterdam
H指数:58
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy

基于流式细胞术的可测量残留病灶评估在接收非强化化疗的急性髓系白血病患者中的应用

2026-03-190
PREAI
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

2025年急性髓系白血病微小残留病更新:ELN-DAVID微小残留病工作组共识文件

Blood
IF23.1
2025-12-160
OAAI
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia

流式细胞术基线可测残留病评估中定量下限作为低水平截断值的预后相关性研究

Leukemia
IF13.4
2025-12-100
OA
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients

高强度治疗患者中急性髓系白血病干细胞定量测定的不同特征。Haematologica

2025-12-012
OA
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial

急性髓系白血病中的计算性微小残留病评估:一项在HOVON-SAKK-132试验中的回顾性验证

Leukemia
IF13.4
2025-09-030
OAAI
The pan-cancer proteome atlas, a mass spectrometry-based landscape for discovering tumor biology, biomarkers, and therapeutic targets

泛癌种蛋白质组图谱,一种基于质谱技术的景观,用于发现肿瘤生物学、生物标志物和 therapeutic targets

2025-05-290
PRE
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
2024-10-050
OAAI
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel
2023-09-067
PRE